Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017040790) ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/040790 International Application No.: PCT/US2016/049913
Publication Date: 09.03.2017 International Filing Date: 01.09.2016
IPC:
C07K 16/28 (2006.01) ,A61K 39/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
Applicants:
AGENUS INC. [US/US]; 3 Forbes Road Lexington, MA 02421, US
LUDWIG INSTITUTE FOR CANCER RESEARCH LTD [CH/CH]; Stadelhoferstrasse 22 CH-8001 Zurich, CH
MEMORIAL SLOAN KETTERING CANCER CENTER [US/US]; 1275 York Avenue New York, NY 10065, US
Inventors:
VAN DIJK, Marc; NL
MUNDT, Cornelia, Anne; DE
RITTER, Gert; US
WOLCHOK, Jedd, David; US
MERGHOUB, Taha; US
ZAPPASODI, Roberta; US
HOLMGAARD, Rikke, Bæk; US
SCHAER, David; US
SAVITSKY, David, Adam; US
WILSON, Nicholas, Stuart; US
Agent:
WIKINS, Andrew, T.; US
Priority Data:
62/212,85101.09.2015US
62/216,04309.09.2015US
62/257,19518.11.2015US
Title (EN) ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF
(FR) ANTICORPS ANTI-PD1 ET MÉTHODES D'UTILISATION DE CEUX-CI
Abstract:
(EN) The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
(FR) La présente invention concerne des anticorps qui se lient spécifiquement au PD-1 humain et ont un effet antagoniste sur la fonction PD-1. L'invention concerne également des compositions pharmaceutiques comprenant ces anticorps, des acides nucléiques codant pour ces anticorps, des vecteurs d'expression et des cellules hôtes permettant de fabriquer ces anticorps, et des méthodes de traitement d'un sujet à l'aide de ces anticorps.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)